MRH Regulatory Sciences
↗San Francisco, USA
MRH Regulatory Sciences is a boutique regulatory affairs consultancy providing strategic guidance and health authority interaction support for pharmaceutical and biotechnology companies. The firm specializes in navigating complex regulatory pathways for oncology, rare diseases, and innovative modalities like radioligand therapies.
Founded by Dr. Myra Herrle following her tenure at POINT Biopharma, the consultancy leverages deep expertise in global filing strategies (IND, NDA, BLA, MAA) and clinical development to accelerate product approvals for its clients.
CLASSIFICATION
SIZE & FINANCIALS
Employees:1-50
Revenue:Under $1M
Founded:2024
Ownership:private
Status:operating
FUNDING
Stage:Bootstrapped
PIPELINE
Stage:Commercial
Lead Drug Stage:N/A (Service Provider)
Modalities:Small molecule, Radioligand therapy, Biologics
Active Trials:0
Trial Phases:-
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Key Partnerships:Client relationships typically include mid-size biotech and radiopharmaceutical startups.
COMPETITION
Position:Niche Player
Competitors:Halloran Consulting Group, Cardinal Health Regulatory Sciences, Parexel, Lachman Consultants
LEADERSHIP
Key Executives:
Myra Herrle - President & Principal Consultant
Scientific Founders:Myra Herrle
LINKS
Website:mrhregsciences.com
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with MRH Regulatory Sciences. The information on this page was collected and compiled using AI agents from publicly available sources. While we strive for accuracy, this data may be incomplete, outdated, or contain errors. For official information, please visit the company's website directly. If you notice any inaccurate information, please contact us.